| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8661883 | International Journal of Cardiology | 2018 | 6 Pages |
Abstract
mTOR-containing regimens can attenuate CAV and CMV risk in HT recipients. A mTOR/MMF combination preserves renal function but increases the risk of ACR.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Douglas L. Jennings, Nicholas Lange, Michael Shullo, Farhana Latif, Susan Restaino, Veli K. Topkara, Koji Takeda, Hiroo Takayama, Yoshifumi Naka, Maryjane Farr, Paolo Colombo, William L. Baker,